Nakashima T, Tomita K, Kuratomi Y, Maehara Y, Kohnoe S
National Kyusyu Cancer Center.
Gan To Kagaku Ryoho. 1990 Jan;17(1):79-84.
In vitro chemosensitivity was evaluated in 28 patients with head and neck squamous cell carcinomas (12 pharyngeal cancers, 7 oral cavity cancers, 4 laryngeal cancers, 4 maxillary sinus cancers and 1 esophageal cancer) and 19 patients with thyroid cancer. Tumor fragments obtained at biopsy or surgery were exposed to anticancer drugs and assayed for succinate dehydrogenase (SD) activity. The average of SD activity in squamous cell carcinomas was 63.2% for 5-FU, 24.6% for HCFU, 26.1% for CDDP, 41.0% for ADM, 28.4% for THP-ADM, 27.1% for ACR, 27.4% for CQ and 45.3% for VLB. In thyroid cancers, the average SD activity was 73.9% for 5-FU, 16.7% for HCFU, 32.6% for CDDP, 48.3% for ADM, 38.3% for THP-ADM, 57.3% for ACR, 39.0% for CQ and 75.3% for VLB. The SD activity inhibition rate by anticancer drugs was larger in cases of head and neck squamous cell carcinomas than in cases of thyroid cancers except for HCFU. Higher sensitivity to each antitumor drug detected in cancer tissues from metastatic lymph-nodes than in tissues from primary lesions needs further investigation.
对28例头颈部鳞状细胞癌（12例咽癌、7例口腔癌、4例喉癌、4例上颌窦癌和1例食管癌）患者和19例甲状腺癌患者进行了体外化学敏感性评估。在活检或手术时获取的肿瘤组织碎片暴露于抗癌药物中，并检测琥珀酸脱氢酶（SD）活性。鳞状细胞癌中，5-氟尿嘧啶（5-FU）的SD活性平均抑制率为63.2%，羟基脲（HCFU）为24.6%，顺铂（CDDP）为26.1%，阿霉素（ADM）为41.0%，吡柔比星（THP-ADM）为28.4%，阿克拉霉素（ACR）为27.1%，长春新碱（CQ）为27.4%，长春碱（VLB）为45.3%。在甲状腺癌中，5-FU的SD活性平均抑制率为73.9%，HCFU为16.7%，CDDP为32.6%，ADM为48.3%，THP-ADM为38.3%，ACR为57.3%，CQ为39.0%，VLB为75.3%。除HCFU外，头颈部鳞状细胞癌患者抗癌药物对SD活性的抑制率高于甲状腺癌患者。在转移淋巴结癌组织中检测到的对每种抗肿瘤药物的敏感性高于原发灶组织，这一现象有待进一步研究。
